Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Department of Thyroid and Breast Surgery, Tianjin Union Medical Center, Tianjin, China.
Front Endocrinol (Lausanne). 2022 Jun 30;13:920857. doi: 10.3389/fendo.2022.920857. eCollection 2022.
Lenvatinib has shown promising efficacy in targeted therapies that have been tested to treat anaplastic thyroid carcinoma (ATC) in both preclinical and clinical studies. The aim of this study was to evaluate the efficacy and safety of lenvatinib in the treatment of patients with ATC.
PubMed, the Cochrane Library, Embase, and ClinicalTrials.gov were searched for potential eligible studies from inception to February 1, 2022. The outcomes included partial response (PR), stable disease (SD), disease control rate (DCR), median progression-free survival (mPFS), and median overall survival (mOS). Effect sizes for all pooled results were presented with 95% CIs with upper and lower limit.
Ten studies met the inclusion criteria. The aggregated results showed that the pooled PR, SD, and DCR were 15.0%, 42.0%, and 63.0%, respectively. The pooled mPFS and mOS were 3.16 (2.18-5.60) months and 3.16 (2.17-5.64) months, respectively. Furthermore, PFS rate at 3 months (PFSR-3m), PFSR-6m, PFSR-9m, PFSR-12m, and PFSR-15m were 52.0%, 22.5%, 13.9%, 8.4%, and 2.5%, respectively. Meanwhile, the 3-month OS rate (OSR-3m), OSR-6m, OSR-9m, OSR-12m, and OSR-15m were 64.0%, 39.3%, 29.7%, 18.9%, and 14.2%, respectively. The most common adverse events (AEs) of lenvatinib were hypertension (56.6%), proteinuria (32.6%), and fatigue (32%).
This meta-analysis showed that lenvatinib has meaningful antitumor activity, but limited clinical efficacy in ATC.
PROSPERO [https://www.crd.york.ac.uk/PROSPERO/], identifier [CRD42022308624].
仑伐替尼在临床前和临床研究中已被证明对治疗间变性甲状腺癌（ATC）具有有前景的疗效，作为靶向治疗药物。本研究旨在评估仑伐替尼治疗 ATC 患者的疗效和安全性。
从建库至 2022 年 2 月 1 日，我们在 PubMed、Cochrane 图书馆、Embase 和 ClinicalTrials.gov 上检索了可能符合条件的研究。结局包括部分缓解（PR）、疾病稳定（SD）、疾病控制率（DCR）、中位无进展生存期（mPFS）和中位总生存期（mOS）。所有汇总结果的效应大小均以 95%CI 及其上限和下限表示。
纳入了 10 项研究。汇总结果显示，PR、SD 和 DCR 的合并率分别为 15.0%、42.0%和 63.0%。合并的 mPFS 和 mOS 分别为 3.16（2.18-5.60）个月和 3.16（2.17-5.64）个月。此外，3 个月时的无进展生存率（PFSR-3m）、PFSR-6m、PFSR-9m、PFSR-12m 和 PFSR-15m 分别为 52.0%、22.5%、13.9%、8.4%和 2.5%。同时，3 个月时的总生存率（OSR-3m）、OSR-6m、OSR-9m、OSR-12m 和 OSR-15m 分别为 64.0%、39.3%、29.7%、18.9%和 14.2%。仑伐替尼最常见的不良反应（AE）是高血压（56.6%）、蛋白尿（32.6%）和疲劳（32%）。
本荟萃分析表明，仑伐替尼对 ATC 具有有意义的抗肿瘤活性，但临床疗效有限。
PROSPERO [https://www.crd.york.ac.uk/PROSPERO/]，标识符[CRD42022308624]。
